Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer

Thermo-Ablation With Radiofrequency Medical Technologies to Treat Thyroid Cancers

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is: • What is the feasibility of RFA use for low-risk thyroid cancers (≤2 cm)? Participants will undergo a set of pre-procedural scans of the target thyroid nodule and undergo the RFA procedure/intervention. Then, participants will partake in three follow-up appointments at 4 weeks, 6 months, and 12 months post-procedure as per standard of care.

Who May Be Eligible (Plain English)

Who May Qualify: 1\. Patients with: - Nodule less than or equal to 2cm in size a. Specifically: Bethesda 5/6 - Their age is ≥18 years and ≤100 years - Able to provide written consent - Able to attend required follow-ups as per the protocol Who Should NOT Join This Trial: - Patients \<18 years old - Pregnant women - Any concern for invasive or metastatic thyroid cancer - Previously treated for thyroid cancer Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1\. Patients with: * Nodule less than or equal to 2cm in size a. Specifically: Bethesda 5/6 * Their age is ≥18 years and ≤100 years * Able to provide written consent * Able to attend required follow-ups as per the protocol Exclusion Criteria: * Patients \<18 years old * Pregnant women * Any concern for invasive or metastatic thyroid cancer * Previously treated for thyroid cancer

Treatments Being Tested

PROCEDURE

Radiofrequency ablation

Radiofrequency energy is delivered to the thyroid nodule via the medical device. This device is a system consisting of 3 main components: 1. VIVA combo RF system (generator and pump) 2. single foot switch 3. electrode (5mm, 7mm, 10mm, or adjustable).

Locations (1)

University Health Network
Toronto, Ontario, Canada